American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer
University of Louisville
500 participants
Jan 1, 2016
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Eligibility
Inclusion Criteria1
- Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.
Exclusion Criteria4
- Have a cardiac pacemaker or ICD implant
- Non-removable implants with metal parts near target lesion
- Myocardial infarction within 3 months prior to enrollment
- Not suitable for general endotracheal anesthesia
Interventions
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02674100